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Abstract
Amyloid-beta (Ab) peptide accumulation in the brain is a pathological hallmark of all forms of Alzheimer’s disease. An
imbalance between Ab production and clearance from the brain may contribute to accumulation of neurotoxic Ab and
subsequent synaptic loss, which is the strongest correlate of the extent of memory loss in AD. The activity of neprilysin
(NEP), a potent Ab-degrading enzyme, is decreased in the AD brain. Expression of HuD, an mRNA-binding protein important
for synaptogenesis and neuronal plasticity, is also decreased in the AD brain. HuD is regulated by protein kinase Ce (PKCe),
and we previously demonstrated that PKCe activation decreases Ab levels. We hypothesized that PKCe acts through HuD to
stabilize NEP mRNA, modulate its localization, and support NEP activity. Conversely, loss of PKCe-activated HuD in AD leads
to decreased NEP activity and accumulation of Ab. Here we show that HuD is associated with NEP mRNA in cultures of
human SK-N-SH cells. Treatment with bryostatin, a PKCe-selective activator, enhanced NEP association with HuD and
increased NEP mRNA stability. Activation of PKCe also increased NEP protein levels, increased NEP phosphorylation, and
induced cell surface expression. In addition, specific PKCe activation directly stimulated NEP activity, leading to degradation
of a monomeric form of Ab peptide and decreased Ab neuronal toxicity, as measured by cell viability. Bryostatin treatment
also rescued Ab-mediated inhibition of HuD-NEP mRNA binding, NEP protein expression, and NEP cell membrane
translocation. These results suggest that PKCe activation reduces Ab by up-regulating, via the mRNA-binding protein HuD,
Ab-degrading enzymes such as NEP. Thus, PKCe activation may have therapeutic efficacy for AD by reducing neurotoxic Ab
accumulation as well as having direct anti-apoptotic and synaptogenic effects.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease characterized by insidious cognitive decline and memory
dysfunction [1]. Synapse loss is the best pathological correlate of
cognitive decline in AD and mounting evidence suggests that AD
is primarily a disease of synaptic dysfunction [2–4]. Soluble
oligomeric forms of amyloid-beta (Ab) peptide, the peptide that
aggregates to form senile plaques in the brain of AD patients, have
been shown to be toxic to neuronal synapses both in vitro and
in vivo and accumulation of Ab peptide plays a central role in the
development of the disease [5–7]. Therefore, preventing the
accumulation of the monomeric form of Ab peptide in the brain
has the potential to prevent neuronal death and memory loss in
AD [8].
Several enzymes degrade Ab peptide, including angiotensin-
converting enzyme (ACE), endothelin-converting enzyme (ECE),
insulin-degrading enzyme (IDE), matrix metalloproteinases
(MMPs), neprilysin (NEP), and plasmin [5,9–11]. Of these, NEP
has been reported as the major physiological Ab peptide-
degrading enzyme in the brain [12,13]. Previous studies have
shown that this enzyme is down-regulated in areas vulnerable to
Ab peptide accumulation in the AD brain [14–17]. Thus,
increasing the expression and activity of NEP in the AD brain
may prevent the accumulation of Ab peptide, protect neurons
against Ab toxicity, and help reverse Ab-related synaptic loss and
cognitive deficits.
We have shown that chronic treatment of Tg2576 AD mice and
an aged rat model with bryostatin, a selective PKCe activator,
dramatically reduces the levels of Ab, recovers the loss of
neurotrophic activity and synapses, and enhances cognitive
function [18,19]. We also previously demonstrated that PKCe
activation up-regulates HuD expression and stimulates its redis-
tribution into the cytosol and dendrites of hippocampal neurons,
where it subsequently controls post-transcriptional expression of
target genes [20]. HuD is an mRNA binding protein that plays a
pivotal role in processing, transport, stability, and local translation
of various mRNAs important for synaptogenesis and neuronal
plasticity in the brain [21–23], such as BDNF and NGF [24] that
are important for neuronal survival, growth and differentiation,
and normal neuronal development [25–27]. The expression levels
of HuD in the brain decrease with age and in the early stages of
AD [12,28]. We hypothesized that PKCe-induced stabilization of
NEP mRNA via HuD protein increases active NEP protein and
activity, thereby abrogating the neurotoxic effects of Ab. In the
AD brain, elevated Ab peptide directly binds to a putative protein
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kinase C (PKCe) substrate domain (Ab 28–30) and inhibits PKCe
translocation and activation [29]. Decreased PKCe leads to a loss
of HuD activation; thus, we further hypothesized that as Ab
accumulates in AD, the subsequent loss of PKCe and HuD activity
leads to a loss of NEP mRNA stability and activity that permits
further Ab accumulation and disease progression. We utilized
cultures of human neuroblastoma cells to determine the mecha-
nistic relationship between PKCe, HuD, and NEP and their roles
in Ab degradation.
Materials and Methods
Cell Culture and Treatments
Human neuroblastoma SK-N-SH cells were obtained from
American Type Culture Collection (ATCC, HTB-11) and were
grown in minimum essential medium supplemented with 1 mM
non-essential amino acids, 100 UI/mL penicillin, 100 mg/mL
streptomycin, and 10% fetal bovine serum (all culture materials
from Invitrogen) under a humidified atmosphere of 5% CO2/95%
air at 37uC. Cells were subcultured 2 times per week and only cells
between passages 4 and 8 were used in experiments. Cells were
treated with combinations of bryostatin (Enzo Life Sciences),
actinomycin D (Enzo Life Sciences), Ro 32–0432 (Bisindolylma-
leimide XI. hydrochloride, Enzo Life Sciences), monomeric or
oligomeric Ab (AnaSpec), or phosphoramidon (Sigma-Aldrich).
Preparation of Ab
For each experiment, monomeric and oligomeric Ab were
prepared from aliquots of the same batch of Ab. To prepare
oligomeric Ab, lyophilized Ab aliquots (0.3 mg) were dissolved in
0.2 mL of 1,1,1,3,3,3-Hexafluoro-2-propanol (HFP, Sigma-Al-
drich) and then added to 0.7 mL of H2O. Samples were loosely
capped and stirred on a magnetic stirrer under a fume hood for
48 hr and then used within 36 hr. Monomeric Ab was prepared
immediately before use by rapidly evaporating the HFP via gently
bubbling nitrogen gas into the solution. The quality of Ab
preparations were routinely checked by dot-blot and immunoblot
with A-11 (1:1,000, Invitrogen) and 6E10 (1:1,000, Covance)
antibodies. The final concentration of the oligomeric Ab
preparation was nominally calculated based on the concentration
of the starting Ab monomer.
Real-time Quantitative Reverse Transcription-polymerase
Chain Reaction (RT-qPCR)
Total RNA was isolated using the RNeasy mini kit (Qiagen) per
the manufacturer’s protocol. For RT reactions, 500 ng of total
RNA was reverse transcribed using oligo(dT) primer and
Superscript III (Invitrogen) at 50uC for 1 hr. Real-time PCR
was performed for 40 cycles with SYBR Green 1 PCR master
mixture and processed on LightCycler 480 II (Roche) machine
using specific primers against human NEP, GAPDH, or histone
(all from Qiagen). Reactions were run in triplicate for each sample
and a dissociation curve was generated. Threshold cycles (Ct) for
NEP amplification were normalized on the house keeping
GAPDH (dCt) and every experimental sample was referred to its
control (ddCt). Relative expression change values were expressed
as 22ddCt.
RNA Binding Protein Immunoprecipitation (RIP) Assay
The RIP assay was performed as described previously [24]. In
brief, cultured cells were lysed in cold lysis buffer (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 100 mM sodium fluoride, 1 mM
sodium orthovanadate, 1 mM EGTA, 1 mM EDTA, 1% Triton
X-100, 2 mM phenylmethylsulfonyl fluoride, 10 mM vanadyl
ribonucleoside complex, 1X complete protease inhibitor cocktail,
and 1X RNase inhibitor [Sigma-Aldrich]) for 15 min at 4uC.
Lysates were spun at 14,0006g for 15 min at 4uC, and
supernatants were incubated overnight with rabbit anti-HuD
polyclonal antibody (Santa Cruz) at 4uC with gentle rotation. After
washing, HuD protein/mRNA complexes were purified using
protein A-magnetic beads and a magnetic separator (both from
Millipore). Total RNA was extracted from the immunocomplexes
Figure 1. HuD protein specifically binds to NEPmRNA in human SK-N-SH cells. A, RIP assay showing HuD-bound NEP mRNA in cultured SK-
N-SH cells. Cells were lysed and immunoprecipitated with normal rabbit immunoglobulin G (NRIgG), HuD antibody, or antibody solution with HuD
peptide and then total RNA was isolated from immunoprecipitates and used for RT-qPCR with specific human NEP primers. As a control, human
GAPDH mRNA was amplified from RT-qPCR of total RNA (Mean 6 SEM of three independent experiments, ***P,0.001, compared with NRIgG). B,
RNA-EMSA assay using recombinant HuD protein and a biotin-labeled oligoriboprobe corresponding to the candidate ARE sequence in 39-UTR region
of NEP mRNA and the 39-UTR of GAPDH mRNA as a negative control, respectively. Unlabeled oligoriboprobe was used as a competitor for the
inhibition reaction.
doi:10.1371/journal.pone.0097756.g001
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with Trizol (Sigma-Aldrich) following the manufacturer’s instruc-
tions and then used for RT-qPCR as described above.
RNA Electrophoretic Mobility Shift Assays (RNA-EMSA)
Oligoribonucleotides containing the candidate adenine- and
uridine-rich instability-conferring element sequence (AU-rich
Figure 2. Activated PKCe stabilizes NEP mRNA. A, Cells were untreated or incubated with HuD siRNA or control siRNA (Con siRNA) for 4 days
and then treated with actinomycin D (ActD, 10 mg/ml) for 2, 4, 6, 8, and 10 hrs. Total RNA was isolated and NEP mRNA was quantified by real time RT-
qPCR. NEP mRNA at each time point was compared with the initial mRNA level (100%). A nonlinear regression analysis was conducted to calculate the
first-order decay constant (k). Average mRNA half-life (t1/2) was calculated as 0.693/k and reported in the table (Mean6 SEM of the three independent
experiments, *P,0.05, HuD siRNA+ActD compared with untreated;#P,0.05, HuD siRNA+ActD compared with Con siRNA-treated). B, mRNA stability
assay from cells treated with ActD or ActD+bryostatin (Bryo, 0.5 nM), or pre-treated with Ro 32-0432 (Ro, 2 mM) for 30 min and then treated with
ActD+Bryo for 2, 4, 6, 8, and 10 hrs. Average mRNA half-life (t1/2) was calculated as 0.693/k and reported in the table (Mean 6 SEM of the three
independent experiments, **P,0.01, ActD+Bryo compared with ActD to assess the bryostatin effect; #P,0.01, ActD+Bryo compared with ActD+Ro+
Bryo to assess the Ro 32-0432 effect). C, Quantitative RT-qPCR analysis showing remaining NEP mRNA from untreated cells or cells incubated with
HuD siRNA or Con siRNA for 4 days (Mean 6 SEM for three independent experiments, **P,0.01, compared with untreated). D, RIP analysis to detect
NEP mRNA associated with HuD protein in untreated cells or cells treated with 0.5 nM Bryo or pre-treated with 2 mM Ro for 30 min and then treated
with Bryo for 1 hr. Relative amounts of NEP mRNA bound to HuD were analyzed by real-time RT-qPCR (Mean 6 SEM for three independent
experiments, ***P,0.001, compared with untreated; #P,0.001, compared with Bryo-treated). E, RIP analysis to detect NEP mRNA associated with
HuD protein in untreated cells or cells incubated with PKCe siRNA or Con siRNA, and then treated without/with Bryo for 1 hr (Mean 6 SEM for three
independent experiments, **P,0.01, compared with untreated; n.s. = not specific).
doi:10.1371/journal.pone.0097756.g002
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element; ARE) from human NEP (5’- UUCUGUGAU-
CAUUUAUUUUAAGCACUC-3’; NM_000902, 2933–2959)
were synthesized and labeled with biotin at the 39-end (Sigma-
Aldrich). As a negative control without the ARE sequence, human
GAPDH 39-UTR (NM_002046) construct (220 bp, Origene) was
used for biotin-labeled ribonucleotide synthesis using the MEGA-
shortscript kit (Life Technologies) following the manufacturer’s
instructions. Biotin-labeled RNA probe (125 nM) was incubated
with purified HuD protein (2 mM, Origene) in binding buffer
(10 mM HEPES, pH 7.3; 20 mM KCl, 1 mM MgCl2, 1 mM
DTT, 5% glycerol, 2 mg/ml tRNA) for 30 min at room
temperature. Unlabeled RNA probe was used as a competitor in
each reaction. After incubation, the RNA-protein mixture was
electrophoresed in a 6% native polyacrylamide gel (Invitrogen) in
0.5X TBE and transferred to a positively charged nylon
membrane. Signals on the blots from the transferred membrane
were detected using a chemiluminescence nucleic acid detection
module (Thermo Scientific) according to the manufacturer’s
protocol.
HuD, PKCe, NEP Gene Silencing
Human HuD-, PKCe-, and NEP-specific siRNA and scrambled
control siRNA were purchased from Santa Cruz. The gene
silencing conditions for each gene were determined by electropo-
ration using the Nucleofector system (Lonza) according to
manufacturer’s specifications. Briefly, SK-N-SH cells (16105
cells/ml) were harvested and resuspended in 100 ml of Nucleo-
fector transfection solution. After transfection of HuD, PKCe,
NEP, or scrambled control siRNA (20 nM), cells were immedi-
ately plated in dishes containing complete media. The following
day cells were split, and 72 hr later either lysed or subjected to
further analyses, as described.
mRNA Stability Assay
mRNA stability was measured by RT-qPCR after the addition
of the transcriptional inhibitor actinomycin D (10 mg/ml) with/
without bryostatin (0.5 nM) to cultured cells for 2, 4, 6, 8, or 10 hr.
To see the effect of PKCe activity, some cells were pre-treated with
a PKCe inhibitor Ro 32–0432 (2 mM) for 2 hr and further
analyzed by RT-qPCR. The amount of NEP mRNA at each time
point was compared with the initial mRNA level (100%). A
nonlinear regression analysis was conducted, which gave a first-
order mRNA decay constant (k). Average mRNA half-life (t1/2)
was calculated as 0.693/k from the equation Mt=M06e
2kt.
Membrane Protein Biotinylation and Detection
Cells treated as above were washed three times with ice-cold
PBS and incubated with PBS containing 1 mg/ml EZ-Link sulfo-
N-hydroxysuccinimide-SS-biotin (Thermo Scientific) at 4uC for
90 min, according to the manufacturer’s instructions. Cells were
then washed three times with ice-cold PBS supplemented with
50 mM Tris (pH 8.0) and finally lysed on ice with lysis buffer for
immunoprecipitation of NEP.
Co-immunoprecipitation (IP) and Immunoblot Analysis
Cultured cells were lysed in cold lysis buffer (10 mM Tris-HCl,
pH 7.4, 5 mM EDTA, 1% Triton X-100, 10% glycerol, 1 mM
CaCl2, 1 mM MgCl2, 1X complete protease inhibitor cocktail,
and 1X phosphatase inhibitor cocktail [Thermo Scientific]) for
1 hr at 4uC. Total lysates (1 mg) were immunoprecipitated with
anti-NEP (Abcam) antibody, and protein/antibody immunocom-
plexes were purified with protein A-magnetic beads and a
magnetic separator (both from Millipore). After washing, im-
munocomplexes were separated by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto
nitrocellulose membranes, and incubated with mouse monoclonal
anti-NEP (1:1,000, Millipore), mouse monoclonal anti- Ab (6E10,
1:1,000, Covance), or rabbit phospho-Ser/Thr (1:500, Abcam)
Figure 3. Activated PKCe enhances HuD binding to NEP mRNA and increases NEP protein expression. A, Immunoblot analyses to detect
HuD and NEP protein levels in untreated cells or cells incubated with control siRNA (Con siRNA) or HuD siRNA (Mean 6 SEM, **P,0.01, compared
with untreated). B, Relative expression of NEP protein was measured by immunoblot analysis after treatment with bryostatin (Bryo, 0.5 nM) or
actinomycin D (ActD, 10 mg/ml), or pre-treatment with ActD for 1 hr prior to bryostatin (ActD+Bryo) for 24 hr (Mean 6 SEM of three independent
experiments, **P,0.01, ***P,0.001, compared with untreated control). C, Immunoblot analyses to detect PKCe and NEP protein levels in untreated
cells or cells incubated with Con siRNA or PKCe siRNA (Mean 6 SEM, *P,0.05, **P,0.01, compared with untreated).
doi:10.1371/journal.pone.0097756.g003
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antibodies. After incubation with horseradish peroxidase (HRP)-
conjugated goat anti-rabbit or mouse IgG (1:10,000; Jackson
ImmunoResearch Lab), the membranes were developed with
Enhanced Chemiluminescence (ECL) Substrate and exposed to X-
ray film (Thermo Scientific). To detect biotinylated NEP proteins,
the membranes were directly incubated with streptavidin-HRP
(Invitrogen), developed with ECL Substrate, and exposed to X-ray
film. As a control, membranes were stripped and re-probed with
mouse anti-NEP or mouse anti-a-tubulin (1:5,000, Sigma-Aldrich)
antibodies followed by HRP-conjugated goat anti-mouse IgG
(1:10,000; Jackson ImmunoResearch Lab). Levels of immunore-
activity were assessed by densitometric analysis of films using an
HP Scanjet densitometer and Image-J image analysis system
software (1.44a, NIH).
Figure 4. Activated PKCe increases phosphorylation and membrane localization of NEP. A, Cells were untreated or treated with
bryostatin (Bryo, 0.5 nM) or pre-treated with Ro 32-0432 (Ro, 2 mM) for 30 min and then treated with Bryo for 1 hr, lysed, and then used for
immunoprecipitation using NEP antibody. Immunocomplexes were further analyzed to detect phosphorylated and biotinylated NEP protein in
immunoblot analyses after normalization for NEP protein level (Mean 6 SEM, *P,0.05, compared with untreated). B, Cells were untreated or
incubated with control siRNA (Con siRNA) or PKCe siRNA for 4 days without/with bryostatin (1 nM) treatment for 1 hr, lysed, and then used for
immunoprecipitation using NEP antibody. Immunocomplexes were further analyzed to detect phosphorylated and biotinylated NEP protein in
immunoblot analyses after normalization for NEP protein level (Mean 6 SEM, **P,0.01, compared with Con siRNA). C, Cells were untreated or
incubated with Con siRNA or HuD siRNA for 4 days, lysed, and then used for immunoprecipitation using NEP antibody. Immunocomplexes were
further analyzed to detect phosphorylated and biotinylated NEP protein in immunoblot analyses after normalization for NEP protein level.
doi:10.1371/journal.pone.0097756.g004
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NEP Activity Assay
NEP activity was measured as described previously [30]. Briefly,
after treatment with PKCe activator bryostatin with/without Ro
32–0432 or phosphoramidon for the indicated times, intact cells
were washed and incubated with 1 mM glutaryl-Ala-Ala-Phe-4-
methoxy-2-naphthylamide (Sigma-Aldrich) solution as a NEP
substrate. The substrate solution was collected and incubated with
leucine aminopeptidase (50 mg/ml, Sigma-Aldrich) in the absence
or presence of 10 mM phosphoramidon for 30 min at 37uC and
the released free 4-methoxy-2-naphthylamide was measured
fluorometrically at an emission wavelength of 425 nm using a
microplate reader (BioTek).
Ab Peptide Degradation Assay
Cells were incubated with 2.5 mg of the monomeric form Ab
peptide 1–42 in a final volume of 100 ml of 50 mM HEPES buffer
(pH 7.2) at 37uC for 4 hr. The reactions were carried out in the
presence or absence of phosphoramidon (10 mM). Proteins and
peptides in the reaction were precipitated using an equal volume
of 20% trichloroacetic acid (TCA, Sigma-Aldrich). All pellets were
resuspended in 2X SDS protein-loading buffer followed by
Figure 5. PKCe activation enhances NEP activity. A, Fluorometric measurement of NEP activity from cells in the absence (untreated) or
presence of bryostatin (Bryo) at 0.27, 0.5, 1, or 2 nM for 1 hr (Mean 6 SEM of three independent experiments, *P,0.05, **P,0.01, Bryo compared
with untreated). B, NEP activity in cells in the absence (untreated) or presence of 1 nM Bryo for 15 min, 30 min, 1 hr, or 3 hr (Mean 6 SEM of three
independent experiments, *P,0.05, **P,0.01, Bryo compared with untreated). C, NEP activity in cells in the absence (untreated) or presence of 1 nM
Bryo, pre-incubated with 2 mM Ro for 30 min, pre-incubated with phosphoramidon (PA, 10 mM, a specific NEP inhibitor) for 5 min, or pre-incubated
with Ro+PA before Bryo treatment for 1 hr (Mean 6 SEM of three independent experiments, **P,0.01, compared with untreated; #P,0.01,
compared with Bryo). D, NEP activity measurement in untreated cells or cells incubated with control siRNA (Con siRNA) or HuD siRNA without or with
treatment of 1 nM Bryo or 2 mM Ro+Bryo for 1 hr (Mean 6 SEM for three independent experiments, **P,0.01, compared with Con siRNA; #P,0.05,
compared with HuD siRNA; $P,0.05, compared with HuD siRNA+Bryo). E, NEP activity measurement in untreated cells or cells incubated with Con
siRNA or PKCe siRNA without or with treatment of 1 nM Bryo or 2 mM Ro+Bryo for 1 hr (Mean6 SEM for three independent experiments, ***P,0.001,
compared with Con siRNA).
doi:10.1371/journal.pone.0097756.g005
PKCe Up-Regulation of Neprilysin-Induced Ab Degradation
PLOS ONE | www.plosone.org 6 May 2014 | Volume 9 | Issue 5 | e97756
immunoblot analyses using anti-Ab peptide antibody 6E10
(1:1,000, Covance) as described above.
Cell Toxicity Assay
Cells were cultured in 48- or 96-well plates at a density of
,3,000–5,000 cells/well in complete growth medium for 24 hr.
Then, growth media was replaced with fresh culture media
(,100–200 ml/well) containing 2.0% FBS and 1 mM oligomeric
Ab peptides 1–42. After 24 hr, cell viability assay was performed
as in a previous study [31] using Cell Counting Kit-8 (Dojindo) by
adding ,10–20 ml of CCK-8 solution to all wells. The plates were
then incubated for 4 hr at 37uC in 5% CO2 and culture medium
was collected and used to measure the absorbance at 450 nm on a
microplate reader (BioTek). The difference in OD relative to
untreated controls was taken as a measure of cell viability and the
percentage of cell viability was calculated by comparing the ODs
at 450 nm of the wells treated with Ab peptides with those of
controls.
Quantification and Statistical Analysis
Quantitative data are expressed in arbitrary units (%) compar-
ing untreated controls with cells treated with bryostatin or the
indicated concentrations of inhibitors. All data are presented as
mean 6 SEM from 3 or more independent experiments unless
otherwise indicated. Statistical comparisons between different
treatment groups were conducted with Tukey’s multiple compar-
ison tests after one-way ANOVA using GraphPad Prism 5
software (GraphPad Software Inc.). P values of less than 0.05
were considered to be statistically significant.
Results
HuD Protein is Specifically Associated with NEP mRNA
To determine whether NEP expression is regulated in human
neuroblastoma cells at the mRNA level by binding to HuD, we
first conducted a RIP assay using a normal HuD antibody. HuD
protein specifically interacted with NEP mRNA, but not with
GAPDH mRNA (Fig. 1A). This interaction was confirmed using
HuD antibody pre-absorbed with a sequence-specific inhibitory
peptide.
HuD is known to bind AU-rich elements (ARE) sequence in the
39-UTR of target mRNAs [32]. We synthesized a biotin-labeled
oligoribonucleotide that includes the highly conserved sequence
(AUUUA) ARE from the human NEP mRNA 39-UTR and
performed an RNA-EMSA assay using recombinant HuD protein.
As a negative control, we used a biotin-labeled oligoribonucleotide
for human GAPDH mRNA 39-UTR, which does not contain an
ARE sequence (Fig. 1B). HuD protein formed complexes with the
NEP mRNA ARE sequence, but not with the GAPDH riboprobe.
Specificity of the HuD-mRNA interaction was confirmed with the
addition of an unlabeled competitor oligoriboprobe.
PKCe Activation Stabilizes NEP mRNA through HuD
Activation
To determine whether HuD protein is important for NEP
mRNA stability and expression in SK-N-SH neuroblastoma cells,
we suppressed HuD expression with specific siRNA against HuD,
and then cultured the cells under transcriptional arrest (induced by
Figure 6. PKCe activation rescues oligomeric Ab-mediated
inhibition of HuD-NEP mRNA interaction and NEP protein
expression. A, RIP analysis to detect NEP mRNA associated with HuD
protein in untreated cells or cells treated with Ab (Abeta, 1 mM), Ab+
bryostatin (Bryo, 0.5 nM) or pre-treated with Ro 32-0432 (Ro, 2 mM) for
30 min and then treated with Abeta+Bryo for 6 hr. Relative amounts of
NEP mRNA bound to HuD were analyzed by real-time RT-qPCR (Mean6
SEM for three independent experiments, **P,0.01, compared with
untreated; #P,0.01, compared with Abeta; $P,0.01, compared with
Abeta+Bryo). B, Relative change in NEP protein expression was
determined based on immunoblot analyses of untreated cells or cells
treated with 1 mM Abeta or Abeta +0.5 nM Bryo, or pre-treated with
2 mM Ro for 1 hr prior to Abeta+Bryo for 24 hr (Mean 6 SEM of the
three independent experiments, *P,0.05, compared with untreated;
#P,0.05, compared with Abeta; $P,0.05, compared with Abeta+Bryo).
doi:10.1371/journal.pone.0097756.g006
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actinomycin D). The decay of NEP mRNA during a 10-hr time
course was measured in the cell lysates by RT-qPCR. As expected,
actinomycin D treatment increased mRNA degradation kinetics,
with a faster decrease in NEP mRNA half-life in cells transduced
with HuD siRNA, compared with untreated or cells transduced
with a scrambled control siRNA (Fig. 2A). We also performed RT-
qPCR to determine the effect of HuD silencing on NEP mRNA
levels. The cells transduced with HuD siRNA showed an
approximate 75% decrease in NEP mRNA, compared with
untreated cells or cells transduced with a scrambled control siRNA
(Fig. 2C). These results indicate that HuD protein is involved in
stabilization of NEP mRNA.
To verify whether PKCe is required for HuD-mediated NEP
mRNA stability, cultured cells under transcriptional arrest
(induced by actinomycin D) were treated without or with the
PKCe activator bryostatin. The decay of NEP mRNA during a
10-hr time course was measured in the cell lysates by RT-qPCR.
Actinomycin D treatment increased mRNA degradation kinetics,
with a decrease in NEP mRNA half-life (Fig. 2B). When cells were
co-treated with bryostatin, the decay rate of the NEP transcript
was delayed, with a dramatic increase in mRNA half-life. The
effect of bryostatin was completely inhibited by pre-treatment of
cells with the PKCe inhibitor Ro 32-0432. This result suggests that
PKCe activation is involved in stabilization of NEP mRNA.
To investigate whether PKCe stabilizes NEP mRNA by
enhancing HuD binding, a RIP assay was performed with anti-
HuD antibody using total mRNA from human cells treated with
bryostatin for 1 hr. Bryostatin treatment induced HuD binding to
NEP mRNA (approximately 3 fold; Fig. 2D). This effect was
almost completely blocked in cells pre-treated with Ro 32-0432 for
30 min. We also tested this effect in cells transduced with PKCe
siRNA compared to untreated cells or cells transduced with a
scrambled control siRNA (Fig. 2E). Cells transduced with PKCe
siRNA showed a 70% decrease in HuD-NEP mRNA binding that
could not be rescued with bryostatin treatment.
To further investigate whether HuD reduction affects NEP
protein expression, we suppressed HuD expression with a specific
siRNA against HuD and measured HuD and NEP protein levels
by immunoblot analysis (Fig. 3A). HuD silencing decreased the
protein levels of HuD and NEP by ,80 and 70%, respectively.
Treatment with bryostatin also led to a significant increase in NEP
protein expression (Fig. 3B). To determine whether PKCe-
stimulated binding of HuD to NEP mRNA affects post-transcrip-
tional regulation, we measured NEP protein levels in cells
transcriptionally arrested by pre-treatment with the transcriptional
inhibitor actinomycin D for 1 hr prior to bryostatin treatment.
Even when transcription is blocked, there was a significant
increase in NEP protein level after bryostatin treatment. We also
examined whether PKCe plays a role in NEP expression,
measuring PKCe and NEP protein levels by immunoblot analysis
under PKCe silencing conditions (Fig. 3C). Cells transduced with
PKCe siRNA showed a decrease in NEP protein level of
approximately 40%. Taken together, these results indicate that
PKCe is involved in HuD-mediated NEP expression and the
increased expression of NEP protein after PKCe activation is
related to post-transcriptional regulation of existing NEP tran-
scripts.
Activated PKCe Increases Phosphorylation and Cell
Membrane Localization of NEP
NEP protein cellular localization and enzymatic activity are
highly dependent on its phosphorylation status [33,34]. We
determined whether the increased NEP expression levels induced
by PKCe could leads to an increase in the activity of NEP by
examining phosphorylation status and membrane localization.
First we found that bryostatin treatment for 1 hr didn’t induced
Figure 7. PKCe activation recovers NEP membrane localization inhibited by oligomeric Ab peptides. A, Cells were untreated or treated
with oligomeric Ab (Abeta; 1 mM) or Abeta+bryostatin (Bryo, 1 nM), or pre-incubated with Ro 32-0432 (Ro, 2 mM) for 30 min before Abeta+Bryo
treatment for 1 hr, and then used for biotin-labeling. Phosphorylated and biotinylated NEP proteins were detected by immunoblot from
immunoprecipitated NEP protein and were compared (Mean 6 SEM of the three independent experiments, *P,0.05, **P,0.01, compared with
untreated; #P,0.05, compared with Abeta; $P,0.05, compared with Abeta+Bryo). B, NEP activity assay from untreated cells or cells treated with 0.5
or 1 mM Abeta, or Abeta +1 nM Bryo, or pre-incubated with 2 mM Ro for 30 min before Abeta+Bryo treatment for 1 hr (Mean 6 SEM for three
independent experiments, *P,0.05, **P,0.01, compared with untreated; #P,0.01, compared with Abeta; $P,0.01, compared with Abeta+Bryo).
doi:10.1371/journal.pone.0097756.g007
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Figure 8. Activated PKCe stimulates NEP activity to protect SK-N-SH cells against Ab neurotoxicity. A, Cells were untreated or treated
with bryostatin (Bryo, 1 nM), phosphoramidon (PA, 10 mM)+Bryo, Ro 32-0432 (Ro, 2 mM)+Bryo, or PA+Ro+Bryo for 1 hr and incubated with
monomeric Ab 1–42 peptide (Abeta, 2.5 mg) for additional 4 hr. Ab 1–42 peptide was precipitated from the reactions by 20% TCA and
immunoblotted with anti-Ab peptide antibody 6E10 (Mean 6 SEM for three independent experiments, **P,0.01, compared with untreated; #P,
0.05, compared with Bryo). B, Ab degradation assay in cells incubated with control siRNA (Con siRNA) or HuD siRNA without or with treatment of
bryostatin (Bryo, 1 nM) or Ro 32-0432 (Ro, 2 mM)+Bryo for 1 hr (Mean 6 SEM for three independent experiments, ***P,0.001, compared with Con
siRNA; #P,0.001, compared with HuD siRNA; $P,0.001, compared with HuD siRNA+Bryo). C, Ab degradation assay in cells incubated with Con siRNA
or NEP siRNA without or with treatment of 1 nM Bryo or 2 mM Ro+Bryo for 1 hr (Mean 6 SEM for three independent experiments, ***P,0.001,
compared with Con siRNA; #P,0.05, compared with NEP siRNA; $P,0.05, compared with NEP siRNA+Bryo). D, Cells were incubated in absence
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NEP protein expression. To test the phosphorylation status of
NEP protein after PKCe activation, we treated cells with
bryostatin for 1 hr, immunoprecipitated NEP from the lysates,
and then performed immunoblot analyses using a phospho-Ser/
Thr antibody. Bryostatin treatment increased NEP phosphoryla-
tion by approximately 2-fold, whereas pre-treatment with Ro 32-
0432 almost completely blocked this effect (Fig. 4A). To investigate
the membrane-localized NEP protein level, cells incubated with
bryostatin for 1 hr were treated with biotin solution to label
membrane-localized proteins. After immunoprecipitation using
NEP antibody and normalization of NEP protein level, biotiny-
lated NEP protein was detected by immunoblot analyses.
Bryostatin treatment induced biotinylation of NEP protein by
approximately 2.1-fold, indicating increased membrane localiza-
tion after PKCe activation, an effect that was almost completely
blocked in cells pre-treated with Ro 32-0432 (Fig. 4A).
To further examine the effect of PKCe on NEP activation, we
suppressed PKCe expression with specific siRNA against PKCe
and measured NEP phosphorylation status and biotinylated NEP
protein levels by immunoblot analysis. NEP protein levels were
normalized to account for the decreased NEP protein level in cells
transduced with PKCe-specific siRNA. PKCe silencing dramat-
ically reduced the levels of phospho-Ser/Thr and biotinylated
NEP protein by ,70% and 75%, respectively. Under PKCe
silencing conditions, treatment with bryostatin did not have an
effect on NEP phosphorylation or membrane localization (Fig. 4B).
These data strongly suggest that activated PKCe phosphorylates
NEP protein and enhances its translocation to the cell membrane.
We also tested whether HuD protein is involved in the
phosphorylation status and membrane localization of NEP
protein. In cells transfected with HuD-specific siRNA, we
measured the phosphorylation status and biotinylated levels of
NEP protein in immunoblot analyses after normalization of NEP
protein level, to account for decreased NEP protein level in cells
transduced with HuD-specific siRNA (Fig. 4C). We found no
difference in phosphorylation status or biotinylated levels of NEP
protein, indicating that HuD plays a role in NEP mRNA stability
and protein expression.
PKCe Activation Enhances NEP Activity
Using a fluorometric peptide substrate, we measured NEP
activity change in human cells treated with different concentra-
tions of bryostatin for 1 hr. At 0.27 nM, bryostatin treatment
slightly increased NEP activity and 0.5 nM of bryostatin
significantly increased NEP activity (Fig. 5A). Cells treated with
1 nM bryostatin showed highest NEP activity (approximately 2-
fold), and NEP activity was slightly lower in cells treated with
2 nM bryostatin. A time course study in cells treated with
bryostatin at 1 nM showed that bryostatin treatment significantly
increased NEP activity at 1 hr, with a decrease in NEP activity by
3 hrs (Fig. 5B). To further investigate the role of PKCe in specific
induction of NEP activity, cells were pre-treated with a PKCe
inhibitor Ro 32-0432, a specific NEP inhibitor phosphoramidon,
or both inhibitors prior to bryostatin treatment. PKCe inhibition
with Ro 32-0432 pre-treatment significantly reduced bryostatin-
induced NEP activation. Incubation with phosphoramidon
completely inhibited bryostatin-induced NEP activity. Cells
treated with both inhibitors showed a further decrease in NEP
activity (Fig. 5C).
We further determined the roles of HuD and PKCe in NEP
activation in cells transduced with HuD- or PKCe-specific siRNA
compared to untreated cells. HuD silencing decreased NEP
activity by ,73%. PKCe activation with bryostatin treatment
increased NEP activation by approximately 26%, compared with
untreated cells under HuD silencing conditions; this effect was
completed blocked by Ro 32-0432 pre-treatment (Fig. 5D). In
addition, we found that PKCe silencing decreased NEP activity by
,80%, and that there was no significant increase in NEP activity
upon bryostatin treatment of cells transduced with PKCe-specific
siRNA (Fig. 5E). These results strongly indicate that activated
PKCe promotes NEP activation in SK-N-SH cells.
Activated PKCe Protects SK-N-SH Cells against Ab Peptide
Accumulation and Toxicity through NEP Stabilization and
Activation
We showed previously that Ab inhibits PKCe and HuD
activation and that bryostatin treatment can reverse the effects of
Ab on HuD and synaptic loss. We wanted to test whether
oligomeric Ab inhibits the HuD-NEP mRNA interaction and if
activated PKCe can rescue the Ab effect. Cells treated with
oligomeric Ab showed a dramatic decrease in HuD-NEP mRNA
binding (Fig. 6A). Co-treatment with bryostatin rescued the
decrease in the HuD-NEP mRNA interaction, an effect that was
completely blocked by PKCe inhibition (Fig. 6A). Oligomeric Ab-
treated cells also showed a significant decrease in NEP protein
levels, which was completely rescued by co-treatment with
bryostatin (Fig. 6B). This effect was also completely blocked by
PKCe inhibition.
We then tested whether Ab exposure inhibits NEP phosphor-
ylation, membrane localization, and activity, and whether
bryostatin activation of PKCe could reverse these effects.
Oligomeric Ab-treated cells showed a significant decrease in
phosphorylated and biotinylated NEP protein by ,60% and 70%,
respectively, indicating a decrease in cell membrane localization of
NEP protein. Co-incubation with bryostatin effectively rescued
oligomeric Ab-inhibited phosphorylation and membrane localiza-
tion of NEP protein by ,40% and 50%, respectively, which were
almost completely blocked by PKCe inhibition (Fig. 7A). We then
tested NEP activity in cells treated with oligomeric Ab (Fig. 7B).
Treatment of cells with oligomeric Ab at 0.5 or 1 mM reduced
NEP activity by 25% or 70%, respectively, consistent with
decreased phosphorylation status and membrane localization level
of NEP protein. Co-treatment with bryostatin effectively recovered
the Ab-mediated decrease in NEP activity; this effect was
completely blocked by PKCe inhibition with Ro 32-0432 pre-
treatment.
To show that PKCe-induced NEP activity degrades Ab, human
neuroblastoma cells were treated with bryostatin with or without
PKCe inhibitor or NEP inhibitor and then exposed to monomeric
Ab 1–42 peptides. Ab peptide degradation assays showed that cells
treated with bryostatin contained less Ab peptide, indicating that
activated PKCe increased NEP activity to effectively degrade the
Ab 1–42 peptide. In contrast, co-treatment with either Ro 32-0432
or phosphoramidon almost completely blocked the effect of
(untreated) or presence of DMSO (vehicle) or oligomeric Ab1–42 peptide (1 mM) for 24 hr. Cells were co-treated with Abeta +0.5 or 1 nM Bryo or pre-
treated with 2 mM Ro for 1 hr or phosphoramidon (PA, 10 mM) for 10 min prior to co-treatment with Abeta+Bryo (1 nM). The viability of the cells after
treatment was determined by cell viability assay and results are expressed as a percentage of viable cells compared with untreated control cells
(Mean 6 SEM of three independent experiments, **P,0.01, compared with untreated; #P,0.05, compared with Abeta; $P,0.01, compared with
Abeta+Bryo).
doi:10.1371/journal.pone.0097756.g008
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bryostatin on Ab degradation (Fig. 8A). To demonstrate whether
the effect of bryostatin on increased Ab degradation is dependent
on HuD or NEP protein level, we examined Ab peptide
degradation assays in cells transduced with HuD- or NEP-specific
siRNA. HuD silencing dramatically inhibited Ab degradation.
PKCe activation was able to enhance Ab degradation, which was
almost completely blocked by PKCe inhibition (Fig. 8B). NEP
silencing also inhibited Ab degradation. PKCe activation slightly
increased Ab degradation, which was completely blocked by
PKCe inhibition (Fig. 8C).
To further demonstrate that the protective effect of activated
PKCe against Ab peptide toxicity in cells occurs through NEP
activation, cells were incubated for 24 hr with culture media
containing 2% FBS with or without oligomeric Ab peptide (1 mM).
Cells were co-treated with bryostatin and either Ro 32-0432 or
phosphoramidon for 24 hr. At the end of the incubation period,
cell viability was quantified. The viability of neuroblastoma cells
was significantly decreased by oligomeric Ab peptide; viability was
increased approximately 30% by 0.5 nM bryostatin treatment and
35% by 1 nM bryostatin treatment. Ro 32-0432 and phosphor-
amidon almost completely blocked the protective effect of
bryostatin, indicating that activated PKCe increases NEP activity
to effectively reduce Ab levels and protect SK-N-SH cells against
Ab peptide toxicity (Fig. 8D).
Discussion
We found that PKCe-regulated HuD protein interacts with the
Ab-degrading enzyme NEP mRNA and increases its stability and
expression, and that activated PKCe is critically important for
NEP localization and activation, leading to decreased Ab levels in
cultured human neuroblastoma SK-N-SH cells. These findings are
consistent with previous studies by our group, which found that
treatment of a mouse model of AD with bryostatin resulted in a
decrease in Ab levels. Our study suggests that the observed effects
of PKCe activation on Ab degradation are mediated by HuD and
the stabilization and activation of the Ab-degrading enzyme NEP.
PKCe activation up-regulates HuD expression and stimulates its
redistribution into the cytosol and dendrites of hippocampal
neurons, where it subsequently controls post-transcriptional
expression of target genes [18]. In addition, PKCe activator
treatment of AD neuronal cells prevents degradation of HuD
mRNA and HuD-associated mRNAs and restores decreased HuD
protein (unpublished data). Our findings extend the current model
of PKCe-mediated Ab degradation to include the interaction of
HuD with NEP mRNA. Bryostatin treatment reversed the
inhibitory effects of Ab on HuD-NEP mRNA binding and NEP
protein expression.
NEP activity correlates to its localization to the cell surface, a
process that is regulated by phosphorylation-dephosphorylation of
the NEP intracellular domain [33,34]. We found that activated
PKCe signaling resulted in increased phosphorylation and cell
membrane localization of NEP, although it remains unclear
whether activated PKCe directly phosphorylates the NEP protein.
Interestingly, casein kinase 2 has been identified as a phosphor-
ylating kinase for NEP that specifically increases NEP activity [33].
Conversely, ERK-mediated phosphorylation decreases NEP Ab-
degrading activity [34], indicating that additional regulation
factors might be involved, and future studies will be performed
to determine whether PKCe plays a direct role in NEP protein
regulation.
Our data further establish NEP as a major factor in the
pathogenesis of AD. Ab peptide in the brain plays a central role in
the pathogenesis of AD [2,4], and alterations in NEP activity likely
affect the development and progression of the disease. In familial
AD, mutations in APP and presenilins are linked to aberrant
increases in the generation of neurotoxic Ab peptides. However, in
sporadic AD, which comprises over 90% of all AD cases, Ab
amyloidosis may be caused by a decline in Ab degradation, Ab
clearance, or both. As a potential therapeutic approach, elevation
of Ab-degrading enzyme expression/activity could promote Ab
degradation and reduce the accumulation of both soluble and
fibrillary Ab in the AD brain [35,36].
We previously showed that overexpressing PKCe in AD
transgenic mice dramatically lowers Ab and plaques in AD
transgenic mice without affecting a-secretase or APP metabolism
[37]. Our current finding–that bryostatin treatment dramatically
reduced Ab levels in monomeric Ab-treated cells in vitro–agrees
with our previous studies showing that in AD transgenic cell lines
that overexpress Ab genes, chronic administration of PKCe
activators bryostatin, DCP-LA, or DHA-CP6 reduces Ab secre-
tion and Ab accumulation, as well as increases ECE activation
[18,38]. In the Tg2576 AD mouse and aged rat models, chronic
bryostatin treatment dramatically reduces the levels of Ab,
recovers the loss of neurotrophic activity and synapses, prevents
neuronal apoptosis, inhibits tau phosphorylation by inhibition
GSK-3b, and enhances synaptogenesis, leading to recovering
cognitive deficits [18,19]. Thus PKCe activators may further
contribute to the treatment of AD, by supporting Ab degradation
via increased NEP activity. To further probe this, in vivo studies of
HuD and NEP activity in various AD animal models are
underway.
Taken together, our results suggest that PKCe triggers HuD-
mediated binding and stabilization of NEP mRNA, which restores
NEP expression and activity. In AD, Ab proteins decrease HuD
expression, and therefore NEP activity, which favors further Ab
accumulation and disease progression. PKCe activators may be
potential therapies that can recover NEP protein levels and activity
in the AD brain, resulting in a reduction of toxic Ab levels, and
restoration of synaptogenesis and cognitive function.
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